The estimated Net Worth of Pharmaceuticals Inc Ligand is at least $360 Million dollars as of 25 August 2020. Pharmaceuticals Ligand owns over 164,488 units of Viking Therapeutics Inc stock worth over $353,993,068 and over the last 16 years Pharmaceuticals sold VKTX stock worth over $6,361,589.
Sign up
Pharmaceuticals Ligand VKTX stock SEC Form 4 insiders trading
Pharmaceuticals has made over 2 trades of the Viking Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals sold 164,488 units of VKTX stock worth $1,327,418 on 25 August 2020.
The largest trade Pharmaceuticals's ever made was selling 262,881 units of Viking Therapeutics Inc stock on 13 July 2017 worth over $5,034,171. On average, Pharmaceuticals trades about 85,474 units every 228 days since 2008. As of 25 August 2020 Pharmaceuticals still owns at least 5,819,383 units of Viking Therapeutics Inc stock.
You can see the complete history of Pharmaceuticals Ligand stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharmaceuticals Ligand's mailing address?
Pharmaceuticals's mailing address filed with the SEC is 3911 SORRENTO VALLEY BOULEVARD,, SUITE 110, SAN DIEGO, CA, 92121.
Insiders trading at Viking Therapeutics Inc
Over the last 9 years, insiders at Viking Therapeutics Inc have traded over $46,107,976 worth of Viking Therapeutics Inc stock and bought 199,715 units worth $855,627 . The most active insiders traders include Brian Lian, Charles A Jr Rowland, and Marianna Mancini. On average, Viking Therapeutics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $4,137,170. The most recent stock trade was executed by Brian Lian on 21 August 2024, trading 1,000 units of VKTX stock currently worth $7,770.
What does Viking Therapeutics Inc's logo look like?
Complete history of Pharmaceuticals Ligand stock trades at Ligand Pharmaceuticals and Viking Therapeutics Inc
Viking Therapeutics Inc executives and stock owners
Viking Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brian Lian,
President, Chief Executive Officer, Director -
Dr. Brian Lian Ph.D.,
Pres, CEO & Director -
Michael Morneau,
Vice President - Finance and Administration -
S. Kathy Rouan,
Independent Director -
Lawson Macartney,
Independent Chairman of the Board -
Charles Rowland,
Independent Director -
J. Matthew Singleton,
Independent Director -
Matthew Foehr,
Director -
Greg Zante,
Senior Vice President - Finance, IR Contact Officer -
Michael Morneau,
VP of Fin. & Admin. -
Marianne Mancini,
Chief Operating Officer -
Gregory S. Zante,
Chief Financial Officer -
Pharmaceuticals Inc Ligand,
10% owner -
Stephen W Webster,
Director -
Rochelle Hanley,
Chief Medical Officer -
Hiroko Masamune,
Chief Development Officer -
Marianna Mancini,
Chief Operating Officer -
Michael Dinerman,
Chief Operating Officer